Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?
2024

Brain Connectivity and Alzheimer's Drug Development

publication Evidence: moderate

Author Information

Author(s): Pini Lorenzo, Lista Simone, Griffa Alessandra, Allali Gilles, Imbimbo Bruno P

Primary Institution: Università degli Studi di Padova

Hypothesis

Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?

Conclusion

Incorporating brain connectivity outcomes could enhance the development of new anti-Alzheimer's drugs by better capturing brain functionality.

Supporting Evidence

  • Brain connectivity studies suggest that misfolded proteins can spread through brain connections.
  • Alzheimer's disease is a multifactorial disorder that requires a new approach to drug development.
  • Functional MRI can be used to assess brain connectivity in Alzheimer's disease.

Takeaway

This study suggests that understanding how different parts of the brain connect can help create better treatments for Alzheimer's disease.

Methodology

The review discusses findings from computational neuroscience and brain connectivity studies related to Alzheimer's disease.

Limitations

The study primarily relies on existing literature and animal models, which may not fully reflect human disease complexity.

Digital Object Identifier (DOI)

10.1093/braincomms/fcae460

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication